Accuray Incorporated (NASDAQ:ARAY) Short Interest Up 12.3% in January

Accuray Incorporated (NASDAQ:ARAY - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 4,030,000 shares, an increase of 12.3% from the December 31st total of 3,590,000 shares. Based on an average trading volume of 624,600 shares, the days-to-cover ratio is presently 6.5 days.

Institutional Trading of Accuray

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in shares of Accuray during the 2nd quarter worth $30,000. US Bancorp DE increased its holdings in Accuray by 1,087.7% in the third quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 16,316 shares in the last quarter. Caprock Group LLC acquired a new stake in shares of Accuray during the 3rd quarter valued at approximately $36,000. Intech Investment Management LLC acquired a new stake in shares of Accuray in the 3rd quarter worth approximately $41,000. Finally, Thrivent Financial for Lutherans purchased a new position in Accuray in the 3rd quarter valued at approximately $57,000. Institutional investors and hedge funds own 64.08% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Accuray from a "buy" rating to a "hold" rating in a research report on Friday, November 15th.

Accuray Stock Performance

Shares of Accuray stock traded up $0.16 during trading on Wednesday, reaching $2.49. The company's stock had a trading volume of 1,558,831 shares, compared to its average volume of 658,405. The company has a 50-day moving average price of $2.09 and a two-hundred day moving average price of $1.96. Accuray has a fifty-two week low of $1.40 and a fifty-two week high of $2.95. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The firm has a market cap of $250.42 million, a PE ratio of -14.65 and a beta of 1.51.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.04). Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. The company had revenue of $101.55 million during the quarter, compared to analysts' expectations of $98.10 million. During the same period last year, the firm earned ($0.03) EPS. On average, analysts forecast that Accuray will post 0.01 EPS for the current year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.